Phase 2 N=28 AZD0530 in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy
Hormone-resistant Prostate Cancer · Recurrent Prostate Cancer
Primary: PSA Response Rate — 0 percentage of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=2 Alpha-lipoic Acid in Patients at Risk for Paclitaxel Induced Neuropathy
Peripheral Neuropathy
Primary: Identification of the Optimal Dose of ALA Based on Acceptable Adverse Event(AE) Profile — 500 mg
N/A N=159 Implementing Sleep Interventions for Older Veterans
Insomnia
Primary: Sleep Onset Latency — 21.3; 31.3 Minutes — p=<.001
Phase 2 N=81 Docetaxel and Bortezomib in Treating Patients With Progressive or Recurrent Non-Small Cell Lung Cancer
Non-small Cell Lung Cancer · Recurrent Non-small Cell Lung Cancer · Stage IV Non-small Cell Lung Cancer
Primary: Overall Response Rate — 10; 10 percentage of participants
Phase 2 N=25 AZD2171 in Treating Patients With Recurrent Small Cell Lung Cancer
Recurrent Non-small Cell Lung Cancer
Primary: Objective Response Rate — 0; 0 percentage of responding patients
N/A N=196 Effect of Intra-abdominal Pressure to the Level of the Sensory Block at Caesarean Section Under Spinal Anesthesia
Obstetric Anesthesia Problems · High-Risk Pregnancy
Primary: The Level of Intra-abdominal Pressure (IAP) — 15.33 mm Hg
Phase 1 N=12 ONCOS-102 (Previously CGTG-102) for Therapy of Advanced Cancers
Malignant Solid Tumour
Primary: Number of Participants With Any (Serious and Non-Serious) Adverse Event Measured to Assess Safety and Tolerability. — 12 participants
Phase 3 N=751 Safety and Immunogenicity of 2 or 3 Doses of MenACWY Conjugate Vaccine in Healthy Infants and the Effects of a Booster Dose of MenACWY Administered in the Second Year of Life
Meningococcal Disease · Meningococcal Meningitis
Primary: Percentage of Subjects With Serum Bactericidal Activity Using Human Complement (hSBA) ≥ 1:8 Against N. Meningitidis Serogroups A, C, W and Y Following a 4-dose Schedule…
N/A N=81 Effects of Different Surgical Methods to Treat Obesity
Obesity · Type 2 Diabetes · Insulin Sensitivity
Primary: Insulin Sensitivity at 2 Years — 6.7; 6.6 glucose/kg body weight/min
Phase 2 N=12 Bryostatin 1 and Cisplatin in Treating Patients With Metastatic or Unresectable Stomach Cancer
Stage III Gastric Cancer · Stage IV Gastric Cancer
Primary: Observed Response Rate. — 0 Percentage of Participants
Phase 2 N=82 A Multi-center, Placebo-controlled Study to Evaluate the Safety of GSK716155 and Its Effects on Myocardial Metabolism, Myocardial Function, and Exercise Capacity in Patients With NYHA Class II/III Congestive Heart Failure
Heart Failure, Congestive
Primary: Change From Baseline in Myocardial Glucose Utilization as Assessed by [18F]Fluoro-2-deoxy-glucose Positron Emission Tomography (FDG-PET) Imaging — 0.0185; 0.0103…
Phase 1 N=36 Safety and Performance of the SinuSys Dilation System for Dilation of the Maxillary Sinus Ostium
Sinusitis
Primary: Patency of Treated Area — 95 percentage of ostia treated
Phase 2 N=38 Part A: Drug Interaction Study of Sofosbuvir and Antiretroviral Therapy (ART) Combinations in HIV and Hepatitis C Virus (HCV) Co-infected Patients. Part B: Efficacy and Safety of Sofosbuvir for 12 Weeks in HIV/HCV Co-infected Patients.
Hepatitis C · HIV
Primary: Part A: Plasma Pharmacokinetics of SOF, EFV, Tenofovir (TFV), and FTC: AUCtau at Day 7 — 867.5; 627.6; 2269.4; 1421.5 h*ng/mL
Phase 4 N=2,902 Immunogenicity, Safety and Tolerability of a Trivalent Subunit Inactivated Vaccine in Healthy Subjects 50 Years and Above
Influenza
Primary: Hemagglutination Inhibition (HI) Geometric Mean Titers (GMTs) of TIV Group and TIVf Group for All Three Strains, in Healthy Adults Aged ≥50 Years — 315; 581; 697; 1048…
Phase 4 N=60 Study to Evaluate the Effects Icodextrin Versus Dianeal on Insulin Resistance in Nondiabetic Automated Peritoneal Dialysis Patients
Disorders Associated With Peritoneal Dialysis
Primary: Adjusted HOMA Index Score at 3 Months Using Baseline Values as a Covariate and Groups as the Fixed Factor — 1.49; 1.89 IR score